Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

HealthDay News — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online January ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)-medications for type 2 diabetes and obesity that have recently been making headlines due to a rise ...

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders.

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...

Weight-loss drugs like Ozempic may decrease your risk of developing 42 health conditions, but increase your chance of ...

Coya Therapeutics, Inc. (NASDAQ:COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have been ...